🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Natália Buza

Yale University

ORCID: 0000-0002-0008-334X

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)”.

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.12.034

N/A

5.8DataRank · unranked

155 citations

Wei Deng, Michael Frumovitz, Natália Buza, Stefania Bellone, Warner K. Huh +7 more

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025

N/A

2.4DataRank · unranked

80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013

N/A

1.9DataRank · unranked

50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00118

N/A

0.626DataRank · unranked

64 citations

Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra +17 more

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Clinical & Experimental Metastasis(2024)10.1007/s10585-024-10297-z

N/A

0.360DataRank · unranked

10 citations

Blair McNamara, Stefania Bellone, Diego Manavella, Cem Demirkiran, Michelle Greenman +16 more

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.009

N/A

0.241DataRank · unranked

4 citations

Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias M.P. Hartwich +24 more

Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6084

N/A

0.104DataRank · unranked

1 citations

Omar Najjar, Molly Klein, Maryam Shahi, Michelle Dolan, Ashley Cimino‐Mathews +9 more

In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0126

N/A

0DataRank · unranked

8 citations

Diego Manavella, Stefania Bellone, Blair McNamara, Justin Harold, Dennis Mauricio +17 more

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2321898121

N/A

0DataRank · unranked

18 citations

Kyungjo Jeong, Mari K. Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman +33 more

Molecular and clinicopathologic characterization of intravenous leiomyomatosis

Modern Pathology(2020)10.1038/s41379-020-0546-8

N/A

0DataRank · unranked

42 citations

Hongyan Chai, Gang Peng, Anna G. McDonald, Michele De Nictolis, Eugenia García‐Fernández +7 more

Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas

Gynecologic Oncology Reports(2024)10.1016/j.gore.2024.101524

N/A

0DataRank · unranked

0 citations

Stefania Bellone, Tobias M.P. Hartwich, Natália Buza, Alessandro D. Santin, Michelle Greenman

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100554

N/A

0DataRank · unranked

8 citations

Natália Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner +4 more

Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.07.016

N/A

0DataRank · unranked

86 citations

Omar Najjar, Shari Damast, Adriana Blakaj, Joan Tymon‐Rosario, Maryam Shahi +10 more

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.014

N/A

0DataRank · unranked

30 citations

Stefania Bellone, Diego Manavella, Levent Mutlu, Blair McNamara, Tobias M.P. Hartwich +17 more